Trevi Therapeutics, Inc. (NasdaqGM: TRVI)
Health Care · Pharmaceuticals · US
$18.00
+0.28% today · +146.6% 1Y
Trevi Therapeutics, Inc. (NasdaqGM: TRVI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.56B and employs 34 people.
Over the last twelve months the share price has gained 146.6%, trading between 6.93 and 20.22.
Tweenvest scores Trevi Therapeutics, Inc. across four factors: quality 27/100. Its strongest factor is quality.
TRVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.56B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $20.22
- 52-week low
- $6.93
- Avg volume (3M)
- —
- Shares outstanding
- 142.48M
- Employees
- 34
- Next earnings
- —
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
- ISIN
- US89532M1018
- Founded
- 2011
- Listed since
- May 7, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.